文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV病毒学抑制者由依曲韦林换用多拉韦林:法国多中心SWEED观察性研究

Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

SWEED为法国10家医院多中心回顾性观察研究,纳入109例依曲韦林方案病毒学抑制的HIV-1成人,换用同药数多拉韦林方案。48周病毒学失败1例(0.9%,95%CI 0.0-5.0),策略成功率91.7%(95%CI 84.9-96.2),4例因不良事件停药,CD4与体重无显著变化。

要点

  • 依曲韦林换用多拉韦林后48周病毒学失败率低,病毒学抑制得以维持。
  • 即使存在既往NNRTI失败史或耐药突变,换药后仍维持病毒学抑制。
  • 多拉韦林日服一次、安全性好、药物相互作用少,支持长期治疗使用。

核心结论

  • 依曲韦林方案换用多拉韦林方案可维持HIV-1感染者病毒学抑制,即使存在既往NNRTI耐药。

研究设计与样本

  • SWEED为法国10家医院多中心回顾性观察研究,纳入109例依曲韦林方案病毒学抑制的HIV-1成人,换用同药数多拉韦林方案,中位随访30个月。

主要发现

  • 48周病毒学失败1例(0.9%,95%CI 0.0-5.0),未换药即重获病毒学抑制。
  • 48周策略成功率91.7%(95%CI 84.9-96.2)。
  • 4例因不良事件停用多拉韦林方案。
  • CD4计数与体重无显著变化。
  • 基线时41%有既往NNRTI失败史,46%对至少一种NNRTI存在耐药突变。

临床怎么用

  • 对依曲韦林方案病毒学抑制的HIV-1成人,可考虑换用同药数多拉韦林方案以简化长期治疗。
  • 换药决策可不受既往NNRTI失败史或耐药突变限制,但仍需个体化评估。

局限性

  • 本研究为回顾性观察性设计,非随机对照,可能存在选择偏倚。
  • 样本量109例,病毒学失败事件仅1例,估计精度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doravirine, the most recent NNRTI, may advantageously replace etravirine in virally suppressed PWH. We evaluated the tolerance and efficacy of doravirine-based ART following a switch from etravirine-based ART. METHODS: SWEED is a national, multicentre, retrospective, observational study including adults with HIV-1 and plasma viral load (pVL) <50 copies/mL on etravirine-based ART, who switched to doravirine-based ART (same number of associated drugs) from 09/01/2019 in 10 French hospitals. The primary outcome was virological failure (VF: confirmed pVL ≥50 copies/mL or single pVL ≥50 with ART change) at week 48 (W48). Secondary outcomes included rates of strategy success (pVL <50 copies/mL with no ART change) and treatment discontinuations due to side effects, and changes in CD4 counts and weight. RESULTS: Among 109 participants (79% men; median age 59 years), median ART duration was 25 years, with 13 years of sustained viral suppression. Prior NNRTI failure was documented in 41% of participants, and 46% had resistance mutations to at least one NNRTI. ART consisted of 2-drug (53%) and 3-drug (42%) combinations. Median follow-up was 30 months. One VF occurred by W48 (0.9%, 95%CI: 0.0-5.0); viral suppression was regained without ART change. Four patients discontinued doravirine-based ART due to adverse events; strategy success rate was 91.7% (95% CI: 84.9-96.2) at W48. No significant changes in CD4 counts and weight were observed. CONCLUSION: Doravirine-based ART maintained virological suppression in PWH switching from etravirine-based ART, even in presence of prior NNRTI resistance. Its once-daily dosing, favourable safety profile, and minimal drug interactions support its use in long-term ART strategies.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Palich R, Ghosn J, Lacombe K, et al. Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study. J Antimicrob Chemother. 2026. PMID: 41187950. doi:10.1093/jac/dkaf410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。